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ABSTRACT
The widespread utilization of gene silencing
techniques, such as antisense, is impeded by the
poor cellular delivery of oligonucleotides (ONs).
Rational design of carriers for enhanced ON delivery
demands a better understanding of the role of the
vector on the extent and time course of antisense
effects. The aim of this study is to understand
the effects of polymer molecular weight (MW) and
ON backbone chemistry on antisense activity.
Complexes were prepared between branched poly-
ethyleneimine (PEI) of various MWs and ONs of
phosphodiester and phosphorothioate chemistries.
We measured their physico-chemical properties and
evaluated their ability to deliver ONs to cells, leading
to an antisense response. Our key finding is that the
antisense activity is not determined solely by PEI
MW or by ON chemistry, but rather by the interplay
of both factors. While the extent of target mRNA
down-regulation was determined primarily by the
polymer MW, dynamics were determined principally
by the ON chemistry. Of particular importance is the
strength of interactions between the carrier and
the ON, which determines the rate at which the ONs
are delivered intracellularly. We also present a
mathematical model of the antisense process to
highlight the importance of ON delivery to antisense
down-regulation.
INTRODUCTION
Antisense technology provides a simple and elegant
means to regulate gene expression, either for therapeutic
purposes or for studying gene function (1–3). With one
FDA approved drug and approximately 20 candidates in
various stages of clinical trials, there is growing promise
for the success of this approach (4,5). Additionally,
the excitement generated by the advent of siRNA has
rejuvenated interest in gene silencing technologies in
general (6). Advances in oligonucleotide (ON) synthesis
have now made it relatively simple to modify the
chemistry of these molecules. This has enabled the
creation of ONs with diverse properties and has thus
greatly widened their overall utilization as speciﬁc
mediators of gene silencing.
With the growing progress in functional genomics, there
is an increasing need for the routine application of gene
silencing tools such as antisense in basic research. Despite
the conceptual simplicity, utilization of antisense as a
routine tool for in vitro studies is greatly impaired by the
poor cellular delivery of these molecules. Delivery of ONs
in a stable form and relevant dose to the appropriate
target site of action remains a considerable challenge to
date (7,8). The reduced cellular entry and rapid degrada-
tion of these molecules in the presence of cellular nucleases
calls for the utilization of carrier molecules. Various types
of carriers, including polymers, lipids and peptides (9–13)
of diverse chemistries, have been tested for their eﬀective-
ness as DNA delivery vectors. However, substantial
optimization is generally required to make these carriers
work for the particular application at hand. The large
variations in vector eﬀectiveness among cell types, as well
as the relatively high cytotoxicity of the currently available
carriers, continue to fuel the demand for more rationally
designed carrier systems (14).
To improve further the design of DNA carriers,
extensive research is being conducted to identify cellular
barriers to carrier mediated delivery of ONs (15). Eﬀorts
are directed towards determining structure–property
relationships that relate carrier properties to antisense
eﬀectiveness. However, it remains somewhat unclear
what factors ultimately dictate the eﬀects observed. Of
particular importance is the fact that much of the
design principles developed for plasmid DNA carriers
are often used interchangeably for antisense ONs
or siRNA. Although this may work in certain cases, the
small size of ONs (10–22 bases) and variations in their
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unique properties that alter their interactions with carriers
in comparison to plasmid DNA, and hence inﬂuence
the design criteria for ON carriers. There are several
examples in literature that point to such diﬀerences in
terms of ON structure, ON chemistry and sequence
composition (16–19). Hence, there is a need for systematic
investigations of the interactions of carriers with ONs,
both at the molecular level as well as at the cellular level,
to acquire a mechanistic understanding of their cellular
processing.
The goal of the present study is to understand the role
of the vector, i.e. the properties of both the carrier and the
ON, on the extent and dynamics of the antisense eﬀect.
For our study, we chose the cationic polymer, polyethyl-
eneimine (PEI), as the model polymer. Our rationale for
doing so is 2-fold. First, PEI is a well characterized carrier
molecule (20). It has been utilized extensively for the
delivery of plasmid DNA due to its high charge density
and endosomolytic activity. Several reviews are available
detailing the eﬀectiveness and mechanism of action of PEI
and its various modiﬁcations for the delivery of DNA to a
range of cell types (21–23). There are fewer studies
focusing speciﬁcally on the delivery of ONs using PEI.
Second, we wish to determine the optimal PEI molecular
weight (MW) for delivery of ONs of various chemistries.
Speciﬁcally, we utilized ﬁve MWs of the branched form of
the polymer, in combination with phosphodiester (PO)
and phosphorothioate (PS) ON backbone chemistries.
While a range of alternative chemistries is now available,
PO and PS ONs are still utilized most often for in vitro
work. We studied the polymer–ON interactions and
further evaluated their eﬃcacy in delivering active anti-
sense ONs to cells. We demonstrate that the observed
antisense eﬀect is not determined solely by the carrier
properties, but by the particular combination of polymer
and ON properties. Of particular importance is the
strength of interactions between the carrier and the ON,
which determines the rate at which the ONs are delivered
intracellularly.
METHODS
Materials
A 20-mer anti-GFP sequence identiﬁed previously (24,25)
as an eﬀective inhibitor of pd1EGFP expression (50-TTG
TGG CCG TTT ACG TCG CC -30) and a scrambled
control (50- TTG CTT GTA CCG TGC GTG CC -30)
were utilized in the study. The phosphodiester, phosphor-
othioate and ﬂuorescently tagged (50 Cy5 end modiﬁed)
forms of these sequences were obtained from Integrated
DNA Technologies (Coralville, IA, USA). Stock solutions
were prepared by reconstituting each pellet in water to a
ﬁnal concentration of 100mM. Branched PEI of molecular
weights 1.2kDa (Cat# 6088), 10kDa (Cat# 19850) and
70kDa (Cat# 00618) was purchased from Polysciences,
Inc. (Warrington, PA). Additionally, PEI of molecular
weight 25kDa (Cat# 408727) and 600–1000kDa (Cat#
3880) was purchased from Sigma. Stock solutions at a
concentration of 10 residue mM (0.43mg/ml) were
prepared in water and the pH adjusted to 7.0 using HCl.
OliGreen, a ﬂuorescent dye that binds strongly to single-
stranded DNA, was obtained from Molecular Probes
(Eugene, OR, USA). Heparin sodium salt was obtained
from Sigma (Cat# H4784). Unless stated otherwise, all cell
culture products were obtained from Invitrogen
(Carlsbad, CA, USA).
PEI/ON complexformation
PEI/ON complexes were prepared at desired PEI/ON
charge ratios by mixing equal volumes of PEI (of
varying concentrations) and ONs in PBS. The samples
were vortexed brieﬂy, and the solutions were then
incubated at room temperature for 10–15min to ensure
complex formation. Experimental evidence (stabilization
of ﬂuorescence corresponding to free ON) conﬁrmed
that this time was suﬃcient for complex formation.
The PEI/ON charge ratios were calculated on a molar
basis. The complexes were prepared at a ﬁnal ON
concentration of 10mg/ml (approximately 1.64mM)
unless stated otherwise.
Detectionof free ON using OliGreen
Complexes between PEI and ONs were prepared at
various charge ratios as described above. One hundred
microliters of each complex solution was transferred to a
96 well (black-walled, clear-bottom, non-adsorbing) plate
(Corning, NY, USA). A total of 100ml of diluted OliGreen
reagent (1:100 in TE buﬀer at pH 8) was then added to all
samples for free ON detection. Fluorescence measure-
ments were made after a 3–5min incubation using a
Cytoﬂuor (Applied Biosystems, CA, USA), at excitation
and emission wavelengths of 485 and 520nm, respectively,
and a voltage gain of 55. All measurements were corrected
for background ﬂuorescence from a solution containing
TE buﬀer and diluted OliGreen reagent.
Determination of particle size using dynamic lightscattering
Complexes were prepared by mixing PEI and ON
solutions (ﬁnal ON concentration of 50mg/ml, charge
ratio of 10:1 in PBS), and immediately analyzed
using a Brookhaven Particle Size Analyzer (Holtsville,
NY, USA) for 15min with readings taken at an
interval of every 3min. Measurements were performed in
triplicate.
PEI/ON dissociation studies
PEI/ON complexes (charge ratio 10:1, ﬁnal ON concen-
tration of 5mg/ml   0.8mM, volume 50ml) were prepared
as described previously and transferred to a 96 well (black
walled, clear bottom, nonadsorbing) plate. One hundred
microliters of diluted OliGreen reagent were added to each
well and mixed manually with a multichannel pipet. Fifty
microliters of heparin solution (at various concentrations
prepared in TE buﬀer at pH 8) were then added to the
wells, and the plate was maintained at 378C. Fluorescence
measurements were made at the end of 1h from the time
of heparin addition using the Cytoﬂuor plate reader.
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ﬂuorescence (F) values as
%ONreleased ¼
½Fðcomplex þ heparinÞ FðON þ heparinÞ 
½FðcomplexÞ FðON þ heparinÞ 
  100
In each measurement, we corrected for changes in
background ﬂuorescence due to heparin addition alone.
This change was found to be dependent on the heparin
concentration (data not shown), and thus was measured
and accounted for in each experiment.
Cellculture
Chinese hamster ovary (CHO-K1) cells (ATCC,
Manassas, VA, USA) were maintained in F-12K
medium (Kaighn’s modiﬁcation of Ham’s F-12; ATCC,
Manassas, VA) supplemented with 10% fetal bovine
serum and penicillin–streptomycin solution. CHO-
d1EGFP cells (CHO-K1 cells stably expressing a destabi-
lized green ﬂuorescent protein transgene) were previously
produced by transfecting CHO-K1 cells with the 4.9kb
d1EGFP-N1 plasmid (BD Biosciences Clontech, Palo
Alto, CA, USA), and maintained under constant selective
pressure by G418 (500mg/ml). All cell lines were cultivated
in a humidiﬁed atmosphere containing 5% CO2 at 378C.
Antisense experiments
CHO or CHO-d1EGFP cells were plated at a density of
1.5 10
5 cells/well in 12 well plates 18h prior to
transfection. Prior to introduction of ONs, cell culture
medium in each well was replaced with 800mlo f
OptiMEM
(R) (reduced serum medium). Further, 200ml
of PEI/ON complex solution prepared in PBS was added
to each well so the ﬁnal ON concentration in each well
(1ml) was 300nM. To measure the intracellular levels
of ONs released from the complexes, cells were treated
with complexes prepared with Cy5-ONs. At the end of the
incubation period of 4h, the transfection mixture was
replaced with serum containing growth medium and
maintained under normal growth conditions (5% CO2,
humidiﬁed atmosphere, 378C). Medium in the wells was
replaced with fresh serum containing medium every 24h.
At various times, cells were assayed for antisense activity
[green ﬂuorescent protein (GFP) ﬂuorescence] and/or ON
levels (Cy5-ON ﬂuorescence) by ﬂow cytometry. As
controls, cells were also exposed to only PEI (in the
absence of ONs), only ONs (in the absence of PEI) as well
as complexes prepared with scrambled ON sequences to
check for sequence speciﬁcity. All times indicated are
relative to when complexes were ﬁrst introduced to the
cells, which represents t=0.
Flow cytometry
Replicate wells of cells were washed in PBS, detached with
trypsin-EDTA, washed with serum-containing medium,
pelleted by centrifugation for 5min at 200g, washed with
PBS, resuspended in 500ml of PBS and maintained on ice
before being subjected to ﬂow cytometry analysis.
Ten thousand cells were analyzed on a FACSCalibur
two-laser, four-color ﬂow cytometer (BD Biosciences) for
GFP ﬂuorescence in FL1 (green) channel and Cy5-ON
ﬂuorescence in FL4 (far-red) channel. CellQuest software
was used to acquire and analyze the results. Viable cells
were gated according to their typical forward/side scatter
characteristics. The ﬂow cytometer was calibrated with
ﬂuorescent beads (CaliBRITE Beads, BD Biosciences)
prior to each use to ensure comparable readings over the
period of the study.
Mathematical model
We previously developed a detailed mathematical model
describing the cellular events that an antisense ON
undergoes in its attempt to reach and block its target in
the cell (26). The model was based on mass action kinetic
equations on the ON and took into account a set of
compartments based on cellular location (e.g. cell
membrane, endosome, cytoplasm) and molecular state
(e.g. free, hybridized or degraded). Here, we present a
simpliﬁed version that describes the intracellular delivery
of ONs and the subsequent antisense response. The
model highlights the signiﬁcance of ON release from
polymer/ON complexes to the overall nature of antisense
down-regulation.
Transfer of ONs from outside the cell to the intracel-
lular space is described as a single process. For the sake of
simplicity, all intermediate steps such as cellular uptake,
endosomal escape and release from PEI/ON complexes
are lumped into this single process. Antisense ONs outside
the cell and inside the cell are each assumed to degrade by
a ﬁrst-order process.
By solution of the governing mass-action kinetic
equations (Appendix), the dynamics of intracellular ON
levels (Ai) can be represented by
AiðtÞ¼  e  t   e  t 
1
Experimental results (Cy5-ON ﬂuorescence) were ﬁt to
Equation (1) using a non-linear equation solver, and the
parameters  ,   and   were estimated. A combination of
these parameters,  (   ), is equal to the initial rate
of intracellular uptake/release of ONs (Appendix,
Equation A4).
Antisense ONs released from PEI/ON complexes
intracellularly are then capable of binding to the target
mRNA to elicit an antisense response. We neglect all other
events such as non-target interactions or protein binding.
Further, we assume the ON-mRNA hybridization to be in
rapid equilibrium, denoted by the equilibrium constant K.
The total mRNA from the target gene can therefore be
present in the unbound or hybridized form. It can be
shown (Appendix) that, following perturbation of the
steady-state with an antisense ON, the amounts of mRNA
and protein, relative to steady-state, m and   respectively,
are given by
d 
dt
¼   1  
 
1 þ KAi t ðÞ

2
d 
dt
¼  
 
1 þ KAi t ðÞ
   

3
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degradation rates (  and   respectively) utilized in the
model were 0.069 and 0.69h
 1, respectively. Given the
Ai(t) proﬁles separately measured and ﬁt to Equation 1,
only the equilibrium constant K remains as an adjustable
parameter. Equations (2) and (3) were solved simulta-
neously for the objective of minimizing the error
associated with K. A more detailed explanation of the
methods employed to solve the model and ﬁt its
parameters is provided in the Appendix.
RESULTS
First, we tested the ability of PEI of molecular weights
ranging from 1.2K to 600K to form complexes with ONs,
as a function of the PEI/ON charge ratio. We measured
the amounts of free (unbound) DNA in solution using a
dye, OliGreen, which ﬂuoresces upon binding to single-
stranded DNA (9,16). As shown in Figure 1, the
ﬂuorescence levels decrease with increasing PEI/ON
charge ratios. At higher charge ratios (>5:1 for PO
ONs or >2:1 for PS ONs), only residual amounts of free
(unbound) ONs are detected in solution, indicating
complex formation. All PEI MWs behave similarly in
their ability to bind with ONs, except that complex
formation is highly ineﬃcient for PEI/PO complexes at the
lowest MW PEI (1.2K). In fact, even at the highest charge
ratio (20:1), there is no signiﬁcant binding between PEI
(MW 1.2K) and PO ONs. Therefore, PEI MW 1.2K was
excluded from all further studies. For all PEI MWs, the
complexation curve is shifted to lower charge ratios for PS
ONs relative to PO ONs, indicating a greater aﬃnity for
the PEI-PS ON interaction.
In order to characterize further the PEI/ON complexes,
particle sizes were estimated in the form of mean
hydrodynamic diameter using dynamic light scattering.
Complexes prepared at various PEI/ON charge ratios in
PBS were subjected to particle size measurements for
15min at a regular interval of 3min. For charge ratios
below 10:1, complexes were found to aggregate, as
indicated by the rapid increase in particle size (data not
shown). Although the OliGreen binding assay indicated
PEI-ON association at these charge ratios, stable,
submicron sized complexes were formed only at a charge
ratio of 10:1 or above. At a charge ratio of 10:1, only
10K/PO complexes displayed particle aggregation, with
the particle diameter increasing from 200 to 450nm within
15min. Irrespective of the PEI MW and ON chemistry, all
other particles were stable in the presence of salt and
maintained a mean diameter of approximately 200nm
(Figure 2). All further studies were therefore performed at
a charge ratio of 10:1.
For eﬀective cellular delivery, polycation–ON com-
plexes should be of an appropriate strength to withstand
encounters with other macromolecular species while
entering the cell and during intracellular traﬃcking but
also to dissociate (unpackage) the ON at some point to
allow recognition of the target mRNA. We probed the
strength of the PEI/ON interactions by studying the
dissociation behavior of these complexes upon exposure to
heparin sulfate as a competitive binding agent (16).
Complexes were prepared at a PEI/ON charge ratio of
10:1, after which heparin was added to dissociate the
complexes, releasing ONs into solution. OliGreen was
used to measure the amount of ONs released, following
subtraction due to the minor eﬀect of heparin on OliGreen
ﬂuorescence. The dose response of ON release with
varying amounts of heparin was determined, using release
at the end of 1h as the measurement. Increasing amounts
of ONs were released with higher doses of heparin for
PEI/ON complexes of both ON chemistries, with several
notable characteristics (Figure 3). For PEI/PO complexes,
the data revealed a threshold heparin concentration above
which most of the ONs were released from the complexes.
There was no signiﬁcant eﬀect of the PEI molecular weight
on the release of PO ONs from PEI. On the other hand,
Figure 1. Eﬀect of PEI molecular weight on complex formation of PEI with (A) PO and (B) PS ONs. Complexes were prepared in PBS at a ﬁnal ON
concentration of 10mg/ml. Fluorescence corresponds to free (unbound) DNA in solution, detected using a commercially available dye OliGreen that
ﬂuoresces upon binding to single-stranded DNA. Data represent mean SD (n=3).
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interactions. Higher amounts of PS ONs were released
with increasing PEI MW (Single factor analysis of
variance (ANOVA) test, p=0.0005, for PEI/PS com-
plexes challenged with heparin at 20mg/ml), indicating
reduced strength of binding between PEI of higher MW
and PS ONs. Furthermore, a comparison of the release
proﬁles for the two ON chemistries indicates enhanced
strength of binding (lesser release) between PEI and PS
ONs as compared to PO ONs.
Having studied the physico-chemical properties of PEI/
ON complexes, we tested the eﬀectiveness of these
polymers in delivering anti-d1EGFP ONs to CHO cells
stably expressing the d1EGFP transgene (9). Cells were
treated with complexes of PEI (various MWs) and ONs
(PS and PO backbone chemistries) for 4h, and subjected
to ﬂow cytometry at each of several times over a 72h time
period. Under all conditions,490% of the cells were gated
as live. The ﬂuorescence levels indicated in Figure 4 are
normalized to the green ﬂuorescence of time-matched,
untreated CHO cells that stably express the d1EGFP
transgene.
Antisense ONs delivered with PEI produced transient
reductions in average GFP levels, with as much as 80%
reduction observed 8h from when cells are treated with
PEI/ON complexes under the best conditions. The time
Figure 3. Heparin dose response of the release of (A) PO and (B) PS ONs from PEI/ON complexes. Complexes (charge ratio 10:1, ﬁnal ON
concentration 5 mg/ml in PBS) were treated with heparin at various concentrations and maintained at 378C for 1h. ONs released from the complexes
were detected using OliGreen as in Figure 1. Data represent mean SD (n=3).
Figure 2. Mean hydrodynamic diameter (nm) of complexes (charge ratio 10:1, ﬁnal ON concentration 50mg/ml in PBS) of PEI with (A) PO and (B)
PS ONs. Data represent mean SD (n 3).
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distinctly with the ON chemistry. As shown in Figure 4A,
PO ONs delivered with PEI produced a rapid and brief
response. GFP levels declined steeply, with as much as
60% of the ﬂuorescence lost in the ﬁrst 4h, when ONs are
delivered with PEI MW 25K. The maximum down-
regulation was observed close to the 8h time point, shortly
after which the GFP levels rise swiftly and return to base
level by 48h from administration. In comparison, PS ONs
delivered with PEI exhibited a more gradual antisense
response that was sustained for a longer duration
(Figure 4B). The antisense eﬀects were maximal between
8 and 24h, and only gradually returned to base level over
a 72h time period. These diﬀerences in the onset of down-
regulation between PO and PS ONs are more distinct at
the earlier time points such as 4h.
Whereas ON chemistry determined primarily the
dynamics of antisense eﬀects, the molecular weight of
PEI used to deliver the ONs inﬂuenced strongly the extent
of down-regulation observed over the same time scale. PO
ONs delivered with intermediate MW PEI (25K) pro-
duced the highest levels of GFP down-regulation, while
lower levels of down-regulation were recorded when PO
ODNs were delivered with all other MWs (10K, 70K and
600K). Interestingly, for PS ONs, the eﬀect of the carrier
MW was more pronounced and quite diﬀerent from that
of PO. Almost no down-regulation was observed when PS
ONs were delivered with the PEI of MW 10 or 25K. In
contrast, almost 80% inhibition was obtained when PS
ONs were delivered with higher MW PEI (70 and 600K).
A number of controls were utilized to evaluate the
contribution of ON labeling dye, free polymer and ON
sequence on GFP down-regulation (Figure 5). When cells
were treated with ONs in the absence of PEI, no antisense
eﬀects (i.e. decrease in GFP expression) were observed,
highlighting the need for a carrier. The carrier itself
exhibited minimal non-speciﬁc eﬀects. We also exposed
cells to complexes of PEI and scrambled anti-GFP
sequences to verify the speciﬁcity of the anti-GFP
sequences. In order to segregate any false eﬀects due to
ineﬃcient/incomplete ON delivery, we used the particular
PEI MW that provided maximum intracellular ON levels
for each of the backbone chemistries, i.e. MW 25K for
PO ONs and MW 70K for PS ONs. In all cases, the
anti-GFP sequences exhibited signiﬁcantly greater
down-regulation than the scrambled ones (Single factor
ANOVA test, p50.01 for complexes of PEI with PO and
PS ONs), providing evidence for reasonable sequence
speciﬁcity of antisense inhibition.
In general, utilization of the d1EGFP transgene as the
antisense target provides a simple means to capture the
antisense down-regulation by measurement of GFP
ﬂuorescence (9,24,25). To detect simultaneously the
presence of delivered, intracellular ONs, ﬂuorescently
(Cy5) end-tagged ONs were utilized in our experiments.
Statistically indistinguishable levels of antisense inhibition
were observed with dye-labeled vs. unlabeled ONs (Single
factor ANOVA test, p40.05, for complexes of PEI with
anti-GFP PO ONs, and for PEI with anti-GFP PS ONs),
indicating that the label did not appreciably alter delivery
or antisense behavior (Figure 5). Because Cy5 tagged ONs
complexed to PEI do not ﬂuoresce (data not shown), the
ON ﬂuorescence measured by ﬂow cytometry corresponds
to ONs released from PEI within cells. Absolute
ﬂuorescence levels are indicated in Figure 6 and are
representative of data from several runs. The levels of
intracellular PO ONs increase rapidly to a maximum at
around 4h after exposure (Figure 6A). PO ONs also
disappear quickly from cells with negligible amounts
detected after 48h. Maximum levels of intracellular PO
ONs are detected when delivered using the intermediate
PEI MW of 25K. In contrast, the levels of intracellular
PS ONs delivered with PEI increase slowly, reaching a
maximum between 8 and 24h after treatment (Figure 6B).
Figure 4. Dynamics of GFP down-regulation. CHO-d1EGFP cells were treated with PEI/Cy5-anti-GFP ON complexes prepared with (A) PO and
(B) PS ONs at a ﬁnal ON concentration of 300nM for 4h under serum-free conditions. At various times, 10000 cells were analyzed for GFP
ﬂuorescence using ﬂow cytometry. GFP ﬂuorescence values are normalized to untreated control cells (100%). Data represent mean SD (n=6).
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being cleared only after 72h. It was interesting to note that
very little ON was detected intracellularly when PEI of
lower MW such as 10K and 25K were used as carriers for
PS ONs. Higher MW PEI (70K, 600K) delivered the
highest amounts of intracellular PS ONs.
To quantify the relationship implied by Figures 4 and 6
between intracellular ON release and antisense inhibition,
we integrated these measurements using a mathematical
model based on mass-action kinetics. By ﬁtting the results
from the ON uptake experiments to a simple lumped
uptake/release process with intracellular and extracellular
degradation (Appendix, Figure A1(a) and Equation A3),
we simulated the dynamics of intracellular ON levels
shown in Figure 7A and B. A comparison of the model ﬁt
to the experimental results in Figure 6A and B shows that
this model captures the dynamics observed in the
intracellular release levels. Using a combination of
parameters obtained from the model ﬁt, we calculated
the initial intracellular ON release rates (k1Ae0) for various
PEI/ON complexes (Table 1). This one parameter
captures the observed PEI MW and ON backbone
dependences. Maximum ON release rates were obtained
with intermediate PEI MW (25K) for PO ONs, while
the higher PEI MW (70K and 600K) release more
PS ONs. This parameter also shows quantitatively that
Figure 6. Dynamics of intracellular ON levels. CHO-d1EGFP cells were treated as described in Figure 4 with PEI/Cy5-anti-GFP ON complexes
prepared with (A) PO and (B) PS ONs. Data represents raw geometric mean ﬂuorescence levels of intracellular Cy5-tagged ONs captured
simultaneously by ﬂow cytometry in a separate channel, while cells are analyzed for their GFP ﬂuorescence levels.
Figure 5. Controls for antisense experiment are described in Figure 4. Data represent treatment with single PEI MW (that delivered maximum PO or
PS ONs), and at a single time point (at which maximum antisense inhibition was detected). The abbreviation ‘sc’ denotes scrambled sequence control,
while ‘Cy-’ denotes ON was tagged at 50 end with Cy5 dye. Data represent mean SD (n =3).
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PS ONs.
Using a mass action kinetic description of ON-mRNA
hybridization (Appendix, Figure A1(b)) and coupling it to
a description of translation (Appendix, Figure A1(c)), we
also modeled the overall antisense dynamics. Estimates of
GFP mRNA half-life from literature vary from 3–12h
(27–30), from which we utilized a half-life of 10h for our
calculations. The protein half-life was estimated as 1h,
which is the nominal value for the destabilized version of
the enhanced d1EGFP. By incorporating these half-life
estimates and the parameters from the ON uptake model,
a single value of the ON-mRNA equilibrium constant
(0.004 and 0.0084 for PO and PS ONs, respectively) was ﬁt
for each ON chemistry across all PEI MWs. As shown in
Figure 7c and d, the GFP down-regulation data
(Figure 4A and B) were captured reasonably well by the
model. Although the maximum down-regulation is some-
what under-predicted, the model predicts accurately the
trends with respect to PEI MW and the overall time scale
of eﬀects for each of the ON chemistries, in particular the
Figure 7. Model predictions of the dynamics of intracellular ON concentrations (A and B) and GFP down-regulation (C and D) in cells treated with
(A and C) PEI/PO and (B and D) PEI/PS complexes, respectively.
Table 1. Maximum intracellular ON release rates (arbitrary units) from
PEI/ON complexes, computed using the ﬁt model parameters
(Equation 1)
PEI MW ON chemistry
PO PS
10K 111.6 15.1
25K 365.9 20.6
70K 273.7 59.4
600K 33.3 86.8
Nucleic Acids Research, 2007, Vol. 35, No. 13 4403delayed onset and sustained activities of PS versus PO
backbones ONs.
DISCUSSION
PEI has garnered signiﬁcant attention in recent times as a
building block for creating eﬀective DNA carriers and has
been tested both in vitro and in vivo to target a large
number of cell types (14,21,31–35). Several modiﬁcations
have been proposed to take advantage of the unique
buﬀering capabilities of this molecule, while reducing the
toxicity associated with its use (36,37). However, most of
these reports focus on delivering plasmid DNA for gene
therapy applications. There are strikingly fewer systematic
studies on the utilization of PEI for single-stranded DNA
molecules. Insights obtained from PEI mediated plasmid
DNA studies are generally extended for the application of
delivering small DNA such as antisense ONs. However, as
noted by us and other researchers (18,31,38), these
generalizations may not hold, especially given the
considerable diﬀerences in the size, structure and chem-
istry between ONs and plasmid DNA. In fact, these small
DNA molecules (10–20 bases) are often observed to
exhibit weaker electrostatic complexation with polycations
due to the small number of charged units per ON
molecules. While the linear form of PEI of MW 25K is
often touted as the most eﬀective carrier for delivering
plasmid DNA, we found it ineﬀective for both PO and PS
ONs (data not shown). Hence, to speciﬁcally identify
issues related to PEI mediated ON delivery, we performed
a systematic study with a set of branched PEI MWs and
ON chemistries.
Using the d1EGFP gene as an easily quantiﬁable
antisense target, we screened various combinations of
PEI MWs (1.2K, 10K, 25K, 70K and 600K) and ON
chemistries (PO and PS) for their ability to elicit an
eﬀective antisense response. For PO ONs, maximum
antisense response was observed with intermediate MW
PEI (25K) as the carrier, while complexes of PS ONs with
higher MW PEI such as 70K and 600K produced
comparable levels of d1EGFP down-regulation. These
particular PEI/ON combinations that achieved highest
antisense response were also the ones that delivered the
most ONs, i.e. maximum intracellular ON levels were
recorded for these cases. Indeed, a monotonic relationship
is apparent when the maximum antisense inhibition is
plotted against the maximum ONs delivered for each
combination of PEI MW and ON chemistry (Figure 8).
Conditions under which no antisense inhibition was
observed occurred because no ONs were delivered using
those particular PEI/ON combinations. A correlation
between intracellular levels of short interfering RNA and
gene silencing has also been reported (39).
Why do diﬀerent combinations of PEI MW and ON
chemistry deliver diﬀerent ON levels? Studies of various
PEI MWs for delivery of plasmid DNA do not provide a
clear view, as they have produced conﬂicting trends. In
some cases, transfection eﬃciency was found to increase
with PEI MW (40), while in others low MW PEI was
eﬀective as a gene delivery agent (35). The toxicity
associated with very high MW PEI oﬀsets its use as
DNA carrier (41), making the less toxic low MW PEI a
more attractive candidate for further improvement despite
its lower net charge density. To date, very little mechan-
istic explanation for the diﬀerences in behavior of various
MWs has been provided. Previous investigations of the
cellular processing of PEI/DNA complexes suggests that
complexes are taken up by binding with proteoglycans,
such as syndecan, and further traﬃcked through the
endocytic pathway (34,42). The similar size of all our
complexes (200nm) suggests a low probability of diﬀer-
ences in the rate of internalization of the complexes. PEI is
believed to enable escape of polyplexes from the endoly-
sosomal pathway by a ‘proton-sponge’ eﬀect, by which
Figure 8. Relationship between antisense inhibition and intracellular ON levels. Each data point represents maximum down-regulation and maximum
ON levels detected when the indicated PEI MW was used to deliver (A) PO and (B) PS ONs. For both sets, results correspond to data obtained 8h
after PEI/ON complexes were introduced to CHO-d1EGFP cells.
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(22,43). It is not clear where or how the DNA is ultimately
released from the complex. Previous studies demonstrate
no signiﬁcant diﬀerences in the buﬀering capacity of PEI
of various MWs in the relevant pH range of 5–7 (20).
Some studies suggest the involvement of cytoplasmic
proteins and other charged molecules in the competitive
release of DNA from PEI/DNA complexes (44).
Therefore, we hypothesize that at least part of the MW
backbone eﬀects could be due to the kinetics of complex
dissociation (unpackaging) and that these could be
evaluated in vitro using the heparin competition assay.
Indeed, the diﬀerences in PEI–ON interactions are
reﬂected in the heparin competition assay, where we
observe a MW dependence on the amount of ONs released
from PEI/PS ON complexes. Speciﬁcally, in the presence
of heparin, complexes made with higher MW release more
PS ONs than complexes made with lower MW PEI.
However, when we tested the strength of the PEI–PO ON
interactions by competition with heparin, we did not ﬁnd
any signiﬁcant diﬀerences among the various PEI MWs.
As such, it appears that the MW inﬂuences delivery of
PO ONs in a manner not captured by the heparin
competition assay, perhaps determining where in the cell
(e.g. endosome versus cytoplasm) the DNA gets released.
Competition with heparin has been used in previous
studies as a measure of the stability of carrier/DNA
complexes. Our studies suggest that higher stability may
correspond to very tight binding that inhibits the release
of DNA from the complexes. There are several such
examples in the literature, wherein polymers that bind
DNA eﬀectively do not release them intracellularly despite
their buﬀering capabilities (36,45). Our results provide
some insights for such observations and additionally
suggest interplay of polymer architecture and ON
chemistry in complex stability versus dissociation. Such
diﬀerences in carrier performance based on ON chemistry
have been observed by others (19). Similar to Dheur et al.
(46), we found PEI 25K ineﬀective for PS ONs, but in
addition, we ﬁnd MWs higher than 25K (such as 70K and
600K) to be eﬃcient in delivering PS ONs.
Apart from identifying higher PEI MWs as eﬀective
carriers for PS ONs, our results more signiﬁcantly
highlight the importance of the strength of the electro-
static interactions between the PEI and ONs, which
ultimately dominates the rate and extent of DNA release.
Both the PEI architecture and ON chemistry play a role in
these interactions. The degree of protonation and the
ﬂexibility of the polymer chains are speculated to be
signiﬁcant. For example, fractured dendrimers that have
more ﬂexible chains are better at delivering plasmid DNA
as compared to intact dendrimers (47). In our system,
higher MW PEI probably possesses more ﬂexible chains,
which are able to interact with the heparin (in our non-
cellular assay) and with unspeciﬁed species in cells, leading
to release of ONs. The role of the ON backbone is
somewhat less clear. Both ON chemistries are known to
have similar charge densities due to the phosphate groups;
however, phosphorothioates are known to be more
hydrophobic than phosphodiesters. The PO and PS
backbones diﬀer only by a single atom: the non-bridging
oxygen is replaced by sulfur in the PS backbone.
Compared to oxygen, the sulfur atom has less electro-
negativity. Studies report that the lower charge density of
the sulfur atom increases its polarizability, strengthening
the interaction with lower charge density groups in
proteins (48,49). This was reﬂected in our PEI–ON
binding assay, in which PS ONs were found to bind to
even the lowest MW of PEI (1.2K). In contrast, 1.2K PEI
and PO ONs did not bind even at very high charge ratios.
Furthermore, PEI–PS ONs displayed higher strength of
interactions in the heparin competition assay. The
manifestation of these molecular interactions on the
cellular processing of the vectors is indeed quite dramatic,
in that some complexes are apparently so tightly bound
that they are incapable of releasing the ONs. As these
interactions can be modulated by appropriate modiﬁca-
tions to carrier and ON properties, they present a design
opportunity for producing an eﬀective antisense response.
We also observed distinctly diﬀerent antisense dynamics
dependent on ON chemistry. The overall antisense
dynamics consists of two phases: (i) the initial onset of
gene inhibition leading to maximum down-regulation and
(ii) the duration for which the antisense eﬀects last. The
latter can be easily explained based on the known
diﬀerences in the resistance of PO and PS ONs to
nucleases. The rapid disappearance of PO eﬀects is
consistent with the susceptibility of PO ONs to intracel-
lular nucleases. PS ONs are known to be more nuclease
resistant and to survive in the cell for longer (50), leading
to sustained antisense eﬀects, which lasted for up to 72h in
our studies.
Based on our previous detailed kinetic modeling (26),
we would expect, for equivalent delivery characteristics,
substantially less silencing of gene expression for PO
versus PS ONs based on the higher nuclease degradation
rate of the former. The fact that we observed signiﬁcant,
albeit short-lived, silencing with some PO ONs suggests
that they are being delivered to the cytoplasm at a faster
rate than their PS counterparts. The dynamics of
intracellular release and gene silencing support this view.
For PO ONs, the onset of gene inhibition was more rapid
with maximum inhibition observed at 8h (Figure 4A). For
PS ONs, the onset was somewhat slower, and antisense
activity was greatest between 8 to 24h from when cells
were ﬁrst exposed to PEI/ON complexes (Figure 4B). A
more rapid intracellular release was also observed with the
PO ONs (Figure 6), although the intracellular release
measurements should be considered under the caveat that
the measured intracellular ﬂuorescence may include
contributions from partially degraded ONs and free
ﬂuorescent tag in addition to delivered, fully intact ON.
Overall, the results suggest that PEI/PS complexes take
longer to release ONs. Our in vitro heparin competition
assay results highlight these diﬀerences in strengths
between PEI and the ONs of PO and PS chemistries
(Figure 3). These results suggest the possibility that a
mixture of PO and PS chemistries would possibly
demonstrate both early and sustained antisense activity
(51). We are currently testing this hypothesis by using PO
backbones with varying degree of PS substitution.
Nucleic Acids Research, 2007, Vol. 35, No. 13 4405Because of the rapidly changing levels of intracellular
Cy5-ON ﬂuorescence and d1EGFP ﬂuorescence at early
times and the discrete time points at which ﬂuorescence in
measured, it can be diﬃcult to discern the diﬀerences in
dynamics among some of the samples. Our mathematical
model of the overall antisense process provides a useful
framework for interpreting these measurements. By ﬁtting
experimental results to a relatively simple function, we
were able to simulate the intracellular ON levels and
calculate intracellular ON release rates from various PEI/
ON complexes. The release rates account quantitatively
for the variation in activity as a function of PEI MW and
also demonstrate a markedly increased release rate for PO
vs. PS ONs (Table 1). To capture the antisense dynamics,
we simpliﬁed the overall antisense process by incorporat-
ing only critical features such as equilibrium ON-mRNA
hybridization. The fact that, with the parameters calcu-
lated from the intracellular ON function and a single
globally optimized parameter (ON-mRNA binding con-
stant), we can ﬁt all of the activity data with ﬁdelity of the
trends, is a further indication that intracellular release
governs the activity to a considerable extent.
Mechanistically this implies that downstream barriers
such as traﬃcking, nucleo-cytoplasmic shuttling, associa-
tion with proteins, and binding to non-target mRNA do
not seem to be as signiﬁcant in governing the dynamics
and MW eﬀects, though they could still be important in a
manner that is not dependent on PEI MW. A similar
approach has been used to identify rate-limiting steps in
siRNA gene silencing in vitro and in vivo (52).
Overall, the results presented here have important
implications for the rational design of polymeric carriers
and ON backbones used for antisense applications. We
have demonstrated that the ﬁnal antisense activity
observed is determined not solely by either carrier or
ON chemistry, but rather by the interplay of both factors.
While the extent of down-regulation was determined
primarily by the polymer MW, the dynamics were
determined chieﬂy by the ON chemistry. Of particular
importance is the strength of interaction between the
carrier and the ON, which determines the rate at which the
ONs are released intracellularly. From a practical
standpoint, our results identify PEI MWs that are eﬀective
for delivering ONs of PO and PS chemistries. This
approach should be useful in predicting and interpreting
results for ONs of other chemistries as well, though it will
be interesting to see to what extent the observed trends
and correlations hold in other cell types. While PEI MW
25K is generally considered the golden standard for
plasmid DNA delivery, this is not true for the delivery of
ONs. More strikingly, we ﬁnd that the performance of a
particular PEI MW is determined by the chemistry of the
ON it is used to deliver. For example, PEI 25K was most
eﬀective in delivering PO ONs, but no PS ONs could be
delivered with the same carrier. Modiﬁcations of polymers
with targeting molecules such as ligands or PEG could
aﬀect the interactions with the ONs and hence inﬂuence
the overall ON release dynamics. Thus, one should be able
to control the onset and duration of antisense activity via
biophysically guided selection of ONs and carriers.
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APPENDIX
Detailsof and solutions tothe mathematical model
Modeling of intracellular ON levels. Transfer of ONs from
outside the cell (Ae) to the intracellular space (Ai)i s
described as a single process, represented by the ﬁrst order
ab c
k1
kde kdi
Ae Ai
Ai + M H MP
δ λ
Φ
ψ
Figure A1. Schematic representing processes taken into consideration
for modeling (a) intracellular antisense ON levels, Ai,( b) mRNA levels,
M and (c) protein levels, P.
Nucleic Acids Research, 2007, Vol. 35, No. 13 4407kinetic rate constant k1. For the sake of simplicity, all
intermediate steps such as cellular uptake, endosomal escape
and release from PEI/ON complexes are lumped into this
single process. Extracellular and intracellular ONs are
assumed to each degrade by a ﬁrst order process represented
by the kinetic rate constants, kde and kdi respectively.
The diﬀerential equations describing the mass balances
of extracellular and intracellular ONs are as follows:
dAe
dt
¼  ð kde þ k1ÞAe ðA:1Þ
dAi
dt
¼ k1Ae   kdiAi ðA:2Þ
Solving these diﬀerential equations subject to the initial
conditions Ae(0)=Ae0 and Ai(0)=0, we obtain
Ai ¼  ðe  t   e  tÞð A:3Þ
where
  ¼ kde þ k1,  ¼ kdi,  ¼
k1Ae0
     
ðA:4Þ
The combination of parameters g(b a)=k1Ae0 therefore
represents the maximum rate of ONs released intracellu-
larly. We ﬁt our experimental data to Equation (A.3)
using the fsolve function in MATLAB, and thus obtain
best-ﬁt estimates for a, b and g for each combination of
PEI MW and ON chemistry used.
Modeling of antisense activity. Antisense ONs released
from PEI/ON complexes intracellularly (Ai) are then
capable of binding to the mRNA (M) to elicit an antisense
response. We neglect all other events such as non-target
interactions or protein binding. Further, we assume the
ON-mRNA hybridization to be in rapid equilibrium,
denoted by the equilibrium constant K. The total mRNA
(MT) from the target gene can therefore be present in the
unbound form (M) or hybridized form (H). The constant
  represents the rate of synthesis of mRNA, while the
degradation of mRNA is described by a ﬁrst order kinetic
constant,  . We assume that only unbound mRNA can be
degraded. Similarly the synthesis and degradation of the
protein (P) are represented by the ﬁrst order kinetic rate
constants   and d, respectively.
The diﬀerential equations describing the mRNA and
protein levels are:
dMT
dt
¼      M ðA:5Þ
dP
dt
¼  M    P ðA:6Þ
The mass balance on the mRNA is:
MT ¼ M þ H ðA:7Þ
Deﬁnition of the equilibrium constant K gives
K ¼
H
MAi
ðA:8Þ
Using (A.7) and (A.8), we obtain an expression for the
fraction of unbound mRNA capable of translation into
protein as,
M
MT
¼
1
1 þ KAi
ðA:9Þ
Solving Equations (A.5) and (A.6) under steady-state
conditions, we obtain the steady-state mRNA and protein
levels:
Mss ¼
 
 
,Pss ¼
 Mss
 
ðA:10Þ
Using these steady-state values, we can non-dimensiona-
lize the equations as follows:
  ¼
MT
Mss
,  ¼
P
Pss
ðA:11Þ
Combining with Equation (A.9), Equations (A.5) and
(A.6) can be represented in dimensionless form as:
d 
dt
¼   1  
 
1 þ KAi t ðÞ

ðA:12Þ
d 
dt
¼  
 
1 þ KAi t ðÞ
   

ðA:13Þ
Incorporating Equation (A.3) into Equations (A.12) and
(A.13) reduces these equations to a three parameter form.
Estimates for   (0.069h
 1) and d (0.69h
 1), which denote
the degradation rates of d1EGFP mRNA and protein
respectively, were obtained from the literature. Our
strategy for obtaining the dynamics of antisense activity
was as follows: using a guess value for K, we simulated the
dynamics of m and   by solving the diﬀerential equations
(A.12) and (A.13) simultaneously using an ODE solver
(ode15s) in MATLAB. By comparing these simulated
dynamics to the experimental results, we computed the
error at each data point. The overall error was calculated
as the SSE (sum of squares of error) over all experimental
time points for all PEI MW for each of the ON chemistries
separately. A new K value was guessed, and the procedure
was repeated until a minimum was achieved for the global
error.
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